STAAR Surgical's Visian Implantable Collamer Lens featured prominently at 2010 ESCRS Congress

NewsGuard 100/100 Score

STAAR Surgical Company (Nasdaq: STAA), the leading worldwide developer, manufacturer and marketer of phakic intraocular lenses, today announced that the Visian Implantable Collamer® Lens (ICL) was featured prominently in more than 40 presentations by leading ophthalmologists at meetings prior to and during the 2010 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) held in Paris, France from September 4 through 8, 2010.  The presentations, based on studies conducted by surgeons throughout the world, confirmed that the Visian ICL offers superior visual results over a wide range of myopic and hyperopic refractive errors including those within the most popular LASIK areas of treatment.  These presentations also confirmed the safety and efficacy of the Visian ICL over a period of 17 years.  

The 7th Annual Visian ICL Expert Meeting, sponsored by STAAR, was held prior to the conference with 100 surgeons from 34 countries in attendance.  There were 26 presentations and eight specialized breakout sessions on ICL topics over a two-day period.  During the opening presentation Hans Blickensdoerfer, President of STAAR Europe, Latin America and the Middle East, demonstrated the growth in Visian ICL procedures by comparing the rate of ICL implants per minute.  In 2008, worldwide, a Visian ICL was implanted every 20 minutes; that rate has doubled in 2010 to one implant every 10 minutes.

"This was our seventh annual meeting of this type and I believe it was the best," commented Mr. Blickensdoerfer.  "We continue to see strong growth in the Visian ICL throughout the world and believe that the newly expanded Visian ICL diopter ranges launched here at ESCRS more than doubles the market opportunity for Visian and allow us to compete directly within the most popular myopic and hyperopic ranges of treatment with LASIK.  Key presentations during the meeting demonstrated that though the Visian ICL has very good results in the higher refractive areas, it can have even better visual results in the lower ranges of refractive procedures where LASIK is most popular currently."

During the formal free paper presentation sessions at the ESCRS meeting there were 17 papers on the Visian ICL, 14 scientific posters and two courses.  All of these continued to reinforce the Visian ICL technology as a safe and effective option for addressing a wide range of myopia, hyperopia and astigmatism.

Some of the highlights during presentations at the Visian ICL Expert's Meeting and the ESCRS included:

  • Dr. Paul Dougherty from the U.S. presented results showing that the Visian ICL was a very safe and effective treatment for lower myopes.  His preference for patients with myopia over 3.0 diopters of refractive error is the Visian ICL.  In his practice the Visian ICL visual results (88% of eyes 20/20 or better), accuracy and safety are better than LASIK.  Ophthalmologists in International markets that accept CE Mark Approval will now be able to treat below 3.0 diopters.
  • Several presentations reinforced the low complication rate of cataract formation in patients with the Visian ICL.
    • Dr. Tobias Neuhann presented the results of the German Study Group, which reflected a 1.4% rate of cataract formation among the 436 patients in the study.
    • In a study of visual outcomes and the safety of the Visian ICL in Chinese eyes, Dr. Xingtao Zhou reported a cataract formation rate of 1.67% in his study of 658 eyes.
    • Dr. Jose F. Alfonso from Spain reported a cataract formation rate of 1.4% in a seven-year study of 734 patients.
    • These studies compare with an incidence of 1.3% anterior subcapsular cataract formation in STAAR's FDA clinical study with five years follow-up.  All eyes with cataract formation were associated with very high myopes, over -12.5 diopters. Only one of those eyes was from a patient younger than 40 years of age.  The total study included 526 eyes.
  • Dr. Scott Barnes from Fort Bragg in the U.S. reported that 75% of the soldiers in which he has implanted the Visian ICL see better now than they did with contact lenses before surgery, and none saw worse.  In contrast only 10% of soldiers who underwent LASIK reported better results than with contact lenses and 50% responded their vision was worse.  The average age reported on was 28 years and over one third of the respondents had a refractive error of -6.0 diopters or less.
  • Dr. Cheryl Lee from Singapore opened an Implantable Lens Centre in January of 2009.  Her experience has been that the quality of vision with the Visian ICL is better than vision with glasses, contact lenses or LASIK.  Her center now has patients walk in to ask for the ICL.

In addition, Dr. Kenneth Lipstock, an ophthalmologist based in Richmond, Virginia and a member of STAAR's CAST (Collamer Accommodating Study Team), presented on the nanoFLEX™ IOL, which uses the same Collamer material of the ICL.  The nanoFLEX, an intraocular lens used for the treatment of cataracts, has demonstrated in early clinical observations the ability to improve near and intermediate vision.  Dr. Lipstock was impressed by the results at near and intermediate vision with the nanoFLEX IOL, reporting that nanoFLEX intermediate visual results were equal to or better than competitive products including Crystalens® HD and 5, ReZOOM® and ReSTOR®.  Dr Lipstock also presented retrospective data on patients where he had used nanoFLEX for monovision treatments. His data showed that with less than a 2 diopter offset, on average his patients could achieve 20/20 distance vision and 20/25 near vision. In Dr. Lipstock's view, the nanoFLEX IOL is a great option for patients who do not want to spend extra money for presbyopic correction.  

On Monday evening, STAAR Surgical sponsored a Symposium on refractive surgery that was attended by over 400 surgeons. In 16 video based presentations, leading global refractive surgeons demonstrated how practitioners can further fine tune success in refractive surgery results.

"The newly expanded indications of the Visian ICL for international markets more than doubles the potential market for the ICL," said Barry G. Caldwell, President and CEO of STAAR.  "The lower diopter range for both myopic and hyperopic patients will now be available in 0.25 diopter increments with new pricing segmentation, which will allow the Visian ICL to compete more effectively with LASIK.  The addition of a Visian Toric Hyperopic ICL and the ability to treat mixed astigmatism will also increase the addressable market with the Visian ICL.  Results from an interactive response system of the attendees at the ICL Expert's Meeting revealed the belief shared by 40% of the group that within five years, 40% of all refractive procedures would be with phakic IOLs."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI offers hope for enhanced cataract surgery in developing nations